• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » A New Medication for Narcolepsy [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts, Android, or Stitcher.

A New Medication for Narcolepsy [60 Sec Psych]

October 28, 2020

Xyrem is a branded form of sodium oxybate, the sodium salt of gamma-hydroxybutyrate, or GHB , to precursor to GABA, glutamate, and glycine which is FDA approved for narcolepsy and cataplexy. The news on Xyrem is that the FDA just approved a new version of it – called Xywav – made by Jazz pharmaceuticals. [FDA Prescribing Information]


Date Published: 10/27/2020


Duration: 2 minutes, 4 seconds


Transcript:

Xyrem is a branded form of sodium oxybate, the sodium salt of gamma-hydroxybutyrate, or GHB , to precursor to GABA, glutamate, and glycine which is FDA approved for narcolepsy and cataplexy. You need to know about it because it’s a heavy sedative and respiratory depressant, and it’s a Schedule III drug of abuse that has also been used as a date rape drug and athletic performance enhancer. You need special certification to prescribe xyrem, and it’s primarily used by neurologists and sleep medicine doctors. Patients actually have to take this sedative in two doses and they have to wake up to take the second dose – first at bedtime and another dose 4 hours later.

You’ll also need to know about it because it’s been studied for alcoholism and fibromyalgia, though the latest fibrom yalgia study was negative.

The news on Xyrem is that the FDA just approved a new version of it – called Xywav – made by Jazz pharmaceuticals. Xywav adds calcium, magnesium, potassium to the mix as binding salts. In other words, while Xyrem is bound only to sodium, Xwav is bound to calcium, magnesium, potassium, and sodium. Both are liquid formulations and both have the same dosing instructions, risks and benefits.

Got feedback? Take the podcast survey.

Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • PB4e_Cover2.png

    Psychiatry Practice Boosters, Fourth Edition (2023)

    Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • autistic_suicidality.jpeg
    Child Psychiatry

    Addressing Suicidality in Autistic Children and Teens

    Autistic kids and teens can become despondent or suicidal. This episode explores the distinction between self-injurious behavior and suicidality in autistic children,...

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.